BCL2 and neoplasm: Other BCL-XL and BCL-2 dual inhibitors developed subsequently (e.g. AZD4320, BM-1197, S44563, APG-1252) also demonstrated similar long-lasting tumour regression in SCLC, gastric and uveal melanoma xenograft models [14–16].